<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cyclophosphamide pulmonary toxicity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cyclophosphamide pulmonary toxicity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cyclophosphamide pulmonary toxicity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ulrich Specks, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R Jett, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> is an alkylating agent that is used in combination with other chemotherapeutic agents for the treatment of a variety of malignant processes. It also has immunosuppressive properties and is used for the treatment of certain autoimmune diseases, either as a sole agent or in combination with glucocorticoids. Long-term use of cyclophosphamide is associated with a multitude of significant side effects, such as hair loss, leukopenia, hemorrhagic cystitis, infertility, the development of secondary malignancies, and pulmonary toxicity.</p><p>The pathogenesis, clinical manifestations, diagnosis, and treatment of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> pulmonary toxicity will be presented here. Other toxicities of cyclophosphamide are discussed separately. (See  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients"</a> and  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Histopathologic findings observed in patients with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> pulmonary toxicity are nonspecific. The characteristic picture is the presence of atypical cells in the alveolar and bronchiolar epithelium, hyperplasia of type II pneumocytes, and interstitial and alveolar edema and fibrosis [<a href="#rid1">1</a>]. Diffuse alveolar damage, organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia or BOOP), and alveolar hemorrhage have been reported [<a href="#rid2">2</a>], and a pattern indistinguishable from usual interstitial pneumonitis (UIP) also can be seen [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease"</a>.)</p><p>Among patients with late onset pulmonary toxicity, a pattern of pleuroparenchymal fibroelastosis can be seen, affecting the upper and lateral aspects of the pleura [<a href="#rid4">4-7</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The parent drug <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is nontoxic to the lung but it is metabolized in the liver, and to a lesser extent in the lung, to the toxic metabolites 4-hydroxycyclophosphamide, acrolein, and phosphoramide mustard [<a href="#rid8">8</a>]. Lung tissue from different species varies in its ability to locally metabolize cyclophosphamide, and susceptibility to cyclophosphamide-induced lung fibrosis in humans may depend upon genetic differences in local pulmonary drug metabolism [<a href="#rid9">9</a>]. Genetic susceptibility is further supported by the absence of a clear dose-response relationship for the development of lung toxicity in humans [<a href="#rid3">3,10</a>].</p><p>In vitro models also suggest the involvement of transforming growth factor-beta in cyclophosphamide-induced pulmonary fibrosis [<a href="#rid11">11</a>]. However, the exact mechanisms by which cyclophosphamide-induced lung injury causes the observed increase in transforming growth factor-beta (TGF-beta) expression and the associated upregulation of collagen synthesis and irreversible fibrosis remain unclear.</p><p class="headingAnchor" id="H7"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Animal models and clinical observations suggest that oxidative stress may contribute to <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> pulmonary toxicity [<a href="#rid9">9</a>]. Concomitant radiation therapy, use of other cytotoxic agents with known lung toxicity (eg, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>), concomitant use of other drugs such as <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> [<a href="#rid12">12-14</a>], and exposure to high inspired oxygen concentrations have all been implicated as additional risk factors for the development of the syndrome [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a> and  <a class="medical medical_review" href="/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p>It is unclear whether a higher total dose of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is a risk factor for lung toxicity, as affected patients have received doses ranging from 150 mg to 81 g [<a href="#rid3">3,14</a>]. On the other hand, when cyclophosphamide is given as a conditioning agent prior to bone marrow transplantation, a dose response has been reported [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H358778829"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Cyclophosphamide-induced pulmonary injury appears to be <strong>rare; the frequency is &lt;1 percent </strong>[<a href="#rid16">16</a>]. However, the risk may be increased by the concomitant use of radiation therapy, oxygen therapy, or other drugs with potential pulmonary toxicity; these factors also may confound attempts to estimate the true incidence of cyclophosphamide-induced lung injury, and to recognize cyclophosphamide-induced pulmonary toxicity when it develops.</p><p>There are two distinct clinical patterns of pulmonary toxicity associated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>: an acute pneumonitis that occurs early in the course of treatment and a chronic, progressive, fibrotic process that may occur after prolonged therapy [<a href="#rid3">3</a>]. A single case of acute pulmonary edema after intravenous cyclophosphamide also has been reported [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H358778835"><span class="h2">Early-onset pneumonitis</span><span class="headingEndMark"> — </span>Affected patients present with cough and dyspnea within one to six months of starting therapy; fever and fatigue also may be present [<a href="#rid1">1,3</a>]. Chest radiographs and computed tomography (CT) scans can show reticular markings and/or a ground glass appearance. Discontinuation of the drug and institution of glucocorticoids usually result in complete resolution of this syndrome.</p><p class="headingAnchor" id="H358778885"><span class="h2">Late-onset pneumonitis and fibrosis</span><span class="headingEndMark"> — </span>Late-onset pulmonary toxicity develops in patients who have received prolonged treatment over several months to years with relatively low doses of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (typically in the setting of immunosuppressive therapy) [<a href="#rid3">3,18</a>]. As an example, five patients with late onset pneumonitis received one to four years of cyclophosphamide therapy and developed lung disease six months to six years after stopping cyclophosphamide [<a href="#rid3">3</a>].</p><p>The clinical picture is one of relentlessly progressive lung fibrosis. The onset of symptoms is insidious, with slowly progressive dyspnea and a nonproductive cough. This disorder differs from usual interstitial pneumonitis (UIP) in that clubbing of the fingers and "velcro-type" inspiratory crackles are lacking, and the diffuse reticular or nodular opacities that are observed on chest radiographs do not have the typical bibasilar predominance seen in UIP. (See  <a class="medical medical_review" href="/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a>.)</p><p>Some patients develop combined pleural and pulmonary fibrosis; these patients are at risk for pneumothorax [<a href="#rid4">4,5,18</a>]. (See <a class="local">'Pathology'</a> above.)</p><p>Late-onset pneumonitis and fibrosis associated with long-term <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> use is minimally responsive to glucocorticoids and to discontinuation of the drug. It almost inevitably leads to terminal respiratory failure.</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> pulmonary toxicity is primarily a clinical diagnosis, based upon symptoms, history of cyclophosphamide use, compatible findings on chest imaging studies, and the absence of an alternative diagnosis (eg, infection, recurrence of underlying disease, hypersensitivity pneumonitis).</p><p class="headingAnchor" id="H9"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Patients with early-onset pneumonitis usually seek medical attention after a short duration of cough, dyspnea, fever, and fatigue [<a href="#rid3">3</a>]. Some patients are asymptomatic, and the disease is suspected because of unexplained radiographic or lung function abnormalities. Late-onset pulmonary toxicity should be suspected when patients with prior or ongoing <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> exposure for six months or longer complain of progressively worsening nonproductive cough and dyspnea. There are no specific symptoms associated with this fibrotic process. (See  <a class="medical medical_review" href="/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>No specific laboratory tests help to establish the diagnosis. Laboratory testing is aimed at the exclusion of other causes for the pulmonary opacities and dyspnea, such as infection or hypersensitivity pneumonitis. (See  <a class="medical medical_review" href="/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H961919852"><span class="h2">Pulmonary function testing</span><span class="headingEndMark"> — </span>Patients with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> pulmonary toxicity typically display a restrictive pattern with a reduced diffusing capacity on pulmonary function testing. Although these findings are diagnostically nonspecific, serial pulmonary function testing may be useful in following the clinical course of these patients.</p><p class="headingAnchor" id="H11"><span class="h2">Chest imaging studies</span><span class="headingEndMark"> — </span>Bilateral reticular or nodular diffuse opacities are the hallmark of both early-onset and late-onset pulmonary toxicity [<a href="#rid3">3</a>]. In the case of early-onset pneumonitis, computed tomography (CT) of the chest reveals "ground-glass" opacities predominantly in the periphery of the upper lungs. (See  <a class="medical medical_review" href="/d/html/6988.html" rel="external">"High resolution computed tomography of the lungs", section on 'HRCT patterns'</a>.)</p><p>The radiographic opacities of late-onset pneumonitis have a more fibrotic appearance on CT; however, nodular opacities with volume loss have been described [<a href="#rid3">3</a>]. The honeycombing pattern characteristic of usual interstitial pneumonitis (UIP) is lacking, and the lower lungs are not predominantly affected. Bilateral pleural thickening of the mid- and upper lung regions is a common feature which also helps in differentiating this process from UIP [<a href="#rid3">3,19-21</a>]. The observed radiographic features of late-onset pneumonitis are similar to those described for pleuroparenchymal fibroelastosis [<a href="#rid3">3,6</a>]. </p><p class="headingAnchor" id="H6776609"><span class="h2">Bronchoscopy</span><span class="headingEndMark"> — </span>The main role of bronchoscopy and bronchoalveolar lavage (BAL) is to exclude other processes such as infection, diffuse alveolar hemorrhage, or, in patients with a malignant disease, lymphangitic tumor spread. (See  <a class="medical medical_review" href="/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"</a> and  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a> and  <a class="medical medical_review" href="/d/html/8252.html" rel="external">"Pulmonary tumor embolism and lymphangitic carcinomatosis in adults: Diagnostic evaluation and management"</a>.)  </p><p class="headingAnchor" id="H12"><span class="h2">Lung biopsy</span><span class="headingEndMark"> — </span>Thoracoscopic and open lung biopsy do not play a significant role in the evaluation of patients with possible <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> pulmonary toxicity unless other conditions such as infection, hypersensitivity pneumonitis, or diffuse malignancy cannot be excluded by other means [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease"</a>.)</p><p>Biopsy findings in late onset pneumonitis are often nonspecific, showing interstitial thickening and an inflammatory infiltrate of lymphocytes with a few neutrophils and eosinophils [<a href="#rid1">1,3</a>]. Well-formed granulomas have been described, distributed along lymphatic pathways associated with nonspecific interstitial pneumonia and hemosiderin deposition [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H14"><span class="h1">TREATMENT AND PROGNOSIS</span><span class="headingEndMark"> — </span>Early-onset pneumonitis is generally a reversible process with a good prognosis, although fatalities have been reported [<a href="#rid1">1</a>]. Most patients respond to discontinuation of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, but the improvement may be gradual; disappearance of symptoms and clearing of chest radiographs may take weeks to months [<a href="#rid3">3</a>].</p><p>The role of glucocorticoids in the treatment of early-onset pneumonitis remains unclear. Most, but not all, successfully treated patients described in the literature have received glucocorticoids, but the magnitude of benefit due to glucocorticoid use (versus treatment discontinuation alone) is unknown [<a href="#rid22">22</a>]. We typically prescribe systemic glucocorticoid therapy in patients with more severe initial symptoms and impairment on pulmonary function testing. The optimal dose is unknown; based on clinical experience we initiate therapy with the equivalent of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 60 mg per day, and taper slowly as tolerated.</p><p>Late-onset pneumonitis with fibrosis is essentially irreversible and follows a chronically progressive course over months to years [<a href="#rid3">3</a>]. Treatment is largely supportive, as systemic glucocorticoids have not been beneficial in reversing fibrosis. Lung transplantation may be considered in selected cases. (See  <a class="medical medical_review" href="/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a>.)</p><p>Mortality due to progressive respiratory failure in late onset pneumonitis is estimated to be over 60 percent [<a href="#rid1">1,3,23</a>].</p><p class="headingAnchor" id="H7156563"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – Cyclophosphamide-induced pulmonary injury appears to be <strong>rare; the frequency is &lt;1 percent</strong>. However, the risk may be increased by the concomitant use of radiation, oxygen therapy, or other drugs with potential pulmonary toxicity. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early-onset acute pneumonitis</strong> – Patients with early-onset <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> pneumonitis develop cough and dyspnea within one to six months after the onset of cyclophosphamide therapy; fever and fatigue also may be present. Key findings on computed tomography include diffuse parenchymal lung disease (eg, areas of consolidation, ground glass opacities, nodular opacities, intralobular septal thickening). (See <a class="local">'Early-onset pneumonitis'</a> above and <a class="local">'Chest imaging studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late-onset pneumonitis</strong> – Late-onset <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> pneumonitis occurs after prolonged (more than six months) treatment with relatively low doses of cyclophosphamide. Presenting manifestations include progressive nonproductive cough and dyspnea. Key findings on computed tomography include interlobular and intralobular septal thickening and often bilateral pleural thickening of the mid- and upper lung regions, but absence of honeycombing. (See <a class="local">'Late-onset pneumonitis and fibrosis'</a> above and <a class="local">'Chest imaging studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> pulmonary toxicity is primarily a clinical diagnosis based on the history of cyclophosphamide use, compatible symptoms and findings on chest imaging studies, and the absence of an alternative diagnosis (eg, infection, recurrence of underlying disease, hypersensitivity pneumonitis). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute pneumonitis</strong> – Early-onset pneumonitis due to <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> should be treated with drug discontinuation; the condition is generally reversible with good prognosis. For patients with severe symptoms or impaired pulmonary function, we suggest use of systemic glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) to assist in relieving pulmonary inflammation. We typically use 60 mg of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> daily or the equivalent, followed by a taper over several weeks based on changes in symptoms. (See <a class="local">'Treatment and prognosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Late-onset pneumonitis</strong> – Late-onset pneumonitis with fibrosis is essentially irreversible and follows a progressive course that is unresponsive to glucocorticoid therapy. Treatment with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> has generally already ceased, but it should be discontinued if still in active use. Lung transplantation may be considered in selected patients. (See <a class="local">'Treatment and prognosis'</a> above and  <a class="medical medical_review" href="/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Segura A, Yuste A, Cercos A, et al. Pulmonary fibrosis induced by cyclophosphamide. Ann Pharmacother 2001; 35:894.</a></li><li><a class="nounderline abstract_t">Myers JL. Diagnosis of drug reactions in the lung. Monogr Pathol 1993; :32.</a></li><li><a class="nounderline abstract_t">Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154:1851.</a></li><li><a class="nounderline abstract_t">Becker CD, Gil J, Padilla ML. Idiopathic pleuroparenchymal fibroelastosis: an unrecognized or misdiagnosed entity? Mod Pathol 2008; 21:784.</a></li><li><a class="nounderline abstract_t">Frankel SK, Cool CD, Lynch DA, Brown KK. Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. Chest 2004; 126:2007.</a></li><li><a class="nounderline abstract_t">Beynat-Mouterde C, Beltramo G, Lezmi G, et al. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J 2014; 44:523.</a></li><li><a class="nounderline abstract_t">Camus P, von der Thüsen J, Hansell DM, Colby TV. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? Eur Respir J 2014; 44:289.</a></li><li><a class="nounderline abstract_t">Kachel DL, Martin WJ 2nd. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994; 268:42.</a></li><li><a class="nounderline abstract_t">Hoyt DG, Lazo JS. Acute pneumocyte injury, poly(ADP-ribose) polymerase activity, and pyridine nucleotide levels after in vitro exposure of murine lung slices to cyclophosphamide. Biochem Pharmacol 1994; 48:1757.</a></li><li><a class="nounderline abstract_t">Trask CW, Joannides T, Harper PG, et al. Radiation-induced lung fibrosis after treatment of small cell carcinoma of the lung with very high-dose cyclophosphamide. Cancer 1985; 55:57.</a></li><li><a class="nounderline abstract_t">Hoyt DG, Lazo JS. Early increases in pulmonary mRNA encoding procollagens and transforming growth factor-beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. J Pharmacol Exp Ther 1989; 249:38.</a></li><li><a class="nounderline abstract_t">Gupta S, Mahipal A. Fatal pulmonary toxicity after a single dose of cyclophosphamide. Pharmacotherapy 2007; 27:616.</a></li><li><a class="nounderline abstract_t">Bhagat R, Sporn TA, Long GD, Folz RJ. Amiodarone and cyclophosphamide: potential for enhanced lung toxicity. Bone Marrow Transplant 2001; 27:1109.</a></li><li><a class="nounderline abstract_t">Sampath S, Schultheiss TE, Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 63:876.</a></li><li><a class="nounderline abstract_t">Spector JI, Zimbler H, Ross JS. Early-onset cyclophosphamide-induced interstitial pneumonitis. JAMA 1979; 242:2852.</a></li><li><a class="nounderline abstract_t">Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med 1990; 11:31.</a></li><li><a class="nounderline abstract_t">Maxwell I. Letter: Reversible pulmonary edema following cyclophosphamide treatment. JAMA 1974; 229:137.</a></li><li><a class="nounderline abstract_t">Hamada K, Nagai S, Kitaichi M, et al. Cyclophosphamide-induced late-onset lung disease. Intern Med 2003; 42:82.</a></li><li><a class="nounderline abstract_t">Alvarado CS, Boat TF, Newman AJ. Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide. J Pediatr 1978; 92:443.</a></li><li><a class="nounderline abstract_t">Abdel Karim FW, Ayash RE, Allam C, Salem PA. Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report. Oncology 1983; 40:174.</a></li><li><a class="nounderline abstract_t">Tsukamoto N, Matsukuma K, Matsuyama T, et al. Cyclophosphamide-induced interstitial pneumonitis in a patient with ovarian carcinoma. Gynecol Oncol 1984; 17:41.</a></li><li><a class="nounderline abstract_t">Mark GJ, Lehimgar-Zadeh A, Ragsdale BD. Cyclophosphamide pneumonitis. Thorax 1978; 33:89.</a></li><li><a class="nounderline abstract_t">Stentoft J. Progressive pulmonary fibrosis complicating cyclophosphamide therapy. Acta Med Scand 1987; 221:403.</a></li></ol></div><div id="topicVersionRevision">Topic 4349 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11485142" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary fibrosis induced by cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8107698" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis of drug reactions in the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8970380" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lung toxicity associated with cyclophosphamide use. Two distinct patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408658" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Idiopathic pleuroparenchymal fibroelastosis: an unrecognized or misdiagnosed entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596706" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24791830" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25082907" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8301583" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7980645" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute pneumocyte injury, poly(ADP-ribose) polymerase activity, and pyridine nucleotide levels after in vitro exposure of murine lung slices to cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2981141" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Radiation-induced lung fibrosis after treatment of small cell carcinoma of the lung with very high-dose cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2709334" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Early increases in pulmonary mRNA encoding procollagens and transforming growth factor-beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381391" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fatal pulmonary toxicity after a single dose of cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438830" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199317" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dose response and factors related to interstitial pneumonitis after bone marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/390173" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Early-onset cyclophosphamide-induced interstitial pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691069" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pulmonary effects of cytotoxic agents other than bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4406810" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Letter: Reversible pulmonary edema following cyclophosphamide treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12583625" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cyclophosphamide-induced late-onset lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/273085" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6843943" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6693052" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cyclophosphamide-induced interstitial pneumonitis in a patient with ovarian carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/644545" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cyclophosphamide pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3604756" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Progressive pulmonary fibrosis complicating cyclophosphamide therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
